Comparing the current results to its competitors, Mdxhealth Sa reported Revenue increase in the 4 quarter 2025 by 0 % year on year. The revenue growth was below Mdxhealth Sa's competitors' average revenue growth of 11.72 %, achieved in the same quarter.
Mdxhealth Sa's Comment on Competition and Industry Peers
The molecular diagnostics industry is characterized by rapid evolution and intense competition, with frequent new product introductions, shifting customer preferences, and significant price competition. The market for prostate cancer diagnostic tests is substantial and includes competitors with greater financial resources, sales capabilities, logistical support, laboratory infrastructure, and experience with third-party payors and marketing. Some competitors are developing serum-based tests and diagnostics that detect proteins, nucleic acids, or mutated gene fragments in blood related to prostate cancer, which may provide technological, financial, reputational, and market access advantages. Industry consolidation is also occurring, enabling larger clinical laboratory service providers to enhance efficiencies and service levels, thereby increasing competitive pressures.
Bioaffinity Technologies Inc is a biotechnology company specializing in developing and commercializing diagnostics for various medical conditions. They utilize their patented platform technology, Affinity™, which enables the detection of cancer and other diseases at an early stage through the use of biomarkers. The company focuses on licensing their technology and partnering with diagnostic companies, aiming to provide accurate, non-invasive, and cost-effective diagnostic solutions.
Exact Sciences Corporation is a medical diagnostics company that specializes in early cancer detection. Their business model involves developing and commercializing non-invasive, DNA-based tests for the detection of colorectal cancer, as well as other cancers and diseases. By leveraging advanced technology and partnerships with healthcare providers, Exact Sciences aims to improve patient outcomes through early detection and intervention.
Guardant Health Inc's business model revolves around providing advanced genomic testing services for cancer patients. It specializes in developing liquid biopsy tests that analyze circulating tumor DNA (ctDNA) in the blood. These tests help in early cancer detection, treatment selection, and monitoring of cancer progression. Guardant Health Inc collaborates with healthcare providers, pharmaceutical companies, and researchers to provide these innovative tests and contribute to the advancement of precision medicine in oncology.
Labcorp Holdings Inc operates as a major healthcare diagnostics company, providing clinical laboratory tests and services to healthcare providers, pharmaceutical companies, and government agencies. Their business model emphasizes delivering accurate and timely test results to aid in patient diagnosis, treatment, and monitoring.
Manhattan Scientifics Inc is a technology-focused company that operates on a licensing business model. They acquire and develop innovative technologies in the fields of medicine, energy, and nanotechnology, and then license these technologies to companies for further development and commercialization. By leveraging their intellectual property portfolio, Manhattan Scientifics Inc generates revenue through licensing agreements and strategic partnerships.
Sources:
Mdxhealth Sa’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Mdxhealth Sa versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
